Humacyte, Inc. (HUMA) Submits Marketing Authorization Application in Israel for Symvess [Yahoo! Finance]
Humacyte, Inc. (HUMA)
Company Research
Source: Yahoo! Finance
17, 2026, Humacyte, Inc. (NASDAQ:HUMA) submitted a Marketing Authorization Application to the Israel Ministry of Health for approval of its acellular tissue-engineered vessel, Symvess, for arterial trauma repair. The company is also pursuing a pathway to make Symvess available in Israel on a hospital-by-hospital basis ahead of potential approval. Symvess is currently approved by the FDA for extremity vascular trauma, while other uses remain investigational and not yet approved by regulatory agencies. Last month, Humacyte, Inc. (NASDAQ:HUMA) presented long-term data on Symvess at the Vascular & Endovascular Surgery Society Annual Winter Meeting 2026. In the V005 trial, the product maintained structural integrity and showed low infection rates with high levels of limb salvage over follow-up periods of up to 36 months. Among 54 patients treated in the Phase 2/3 study where standard vein grafts were not feasible, outcomes stabilized after early complications, with infection-free rates r
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Wall Street Analysts Think Humacyte, Inc. (HUMA) Is a Good Investment: Is It? [Yahoo! Finance]Yahoo! Finance
- Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026GlobeNewswire
- Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi ArabiaGlobeNewswire
- Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common StockGlobeNewswire
- Humacyte (HUMA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.MarketBeat
HUMA
Earnings
- 11/12/25 - Beat
HUMA
Sec Filings
- 3/19/26 - Form 8-K
- 3/19/26 - Form 424B3
- 3/19/26 - Form 8-K
- HUMA's page on the SEC website